Takeda builds arsenal for immuno-oncology research, creates cell therapy group

Takeda’s presence in cancer — fortified by its $5.2 billion Ariad buyout — is growing, as it announced a range of agreements in immuno-oncology and the creation of a cell therapy unit, days before the Japanese drugmaker consummates its $62 billion takeover of Dublin-based Shire.